Class 4 Drug Caution In Use - NovoRapid FlexTouch 100 units/ml and Saxenda FlexTouch® (liraglutide) 6mg/ml

Novo Nordisk Limited would like to notify you of a defect that affects specific batches of NovoRapid FlexTouch prefilled pen device and batches of Saxenda FlexTouch prefilled pen device in the UK. The defect results in a non-functioning device where it is not possible to set a dose because the dose selector will spin freely, as such, click sounds will not be heard. Since a dose cannot be selected, the patient cannot inject a dose. A very small number of pens are affected – the average number of affected products is 2-3 pens per million pens. Based on the critical need for the products, they are not being recalled.

MHRA drug alert date: 21 July 2022

MHRA drug alert link:

https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-novo-nordisk-limited-novorapid-r-flextouch-r-100-units-slash-ml-saxenda-r-flextouch-r-liraglutide-6mg-slash-ml-el-22-a-slash-33?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=d1821ab9-5a71-4493-a0b8-973140c8ca04&utm_content=immediately

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to Novo Nordisk Limited.

Further Information

For medical information and stock control queries please contact: Customer Care contact details +44 (0)800 023 2573 or CustomerCare@novonordisk.com